The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon reaching specific regulatory milestones. This strategic acquisition is anticipated to conclude in the third quarter of 2024, subject to customary closing and regulatory approvals.

Amolyt Pharma, known for its innovative therapeutic peptides, is at the forefront of addressing the unmet needs within the rare disease community. The company has notably progressed eneboparatide, a leading compound in Phase 3 trials for hypoparathyroidism, alongside a promising early-stage pipeline developed in under five years. This acquisition by Alexion, AstraZeneca's arm specializing in rare diseases, marks a significant milestone in enhancing the global reach of Amolyt's groundbreaking therapies.

Thierry Abribat, Ph.D., the founder and CEO of Amolyt Pharma, expressed gratitude towards the team's accomplishments and the support from the patient and medical communities. He anticipates the accelerated development and expanded reach of their portfolio under Alexion, AstraZeneca Rare Disease.

Pierre Legault, Chairman of Amolyt Pharma’s Board, highlighted the deal's value to shareholders and patients, expressing confidence in Alexion's ability to advance Amolyt's scientific innovations to patients worldwide.

Marc Dunoyer, CEO of Alexion, underscored the acquisition's strategic fit, particularly pointing to eneboparatide's potential to meet the critical needs of chronic hypoparathyroid patients. He emphasized Alexion's commitment to leveraging Amolyt's expertise and pipeline to broaden its impact in rare endocrinology.

The transaction will see AstraZeneca acquiring all outstanding shares of Amolyt Pharma for a total consideration of up to $1.05 billion, on a cash and debt-free basis. This acquisition highlights AstraZeneca's ongoing commitment to expanding its footprint in the rare disease and endocrinology sectors, promising enhanced treatment options for patients globally.